相关实验视频
Updated: Jan 13, 2026

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
821
有选择性和口服生物可用的二乙酶9抑制剂具有强烈的热致死诱导特性
Nicolò Filippi1, Kathleen Mertens2, Joni De Loose2
1Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium.
Journal of medicinal chemistry
|October 29, 2025
概括
新型的二二甲酶9 (DPP9) 抑制剂在白血病和HIV-1感染细胞中显示出强烈的热致死诱导作用. 化合物6e在老鼠中表现出极好的口服生物可用性和半衰期,具有潜在的治疗应用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 滴基化酶9 (DPP9) 调节白细胞中的热.
- DPP9 抑制剂在治疗急性髓性白血病 (AML) 和HIV-1 感染方面表现有前途.
研究的目的:
- 报告新型低纳米 DPP9 抑制剂的结构-活性关系数据.
- 为了评估这些抑制剂的激素灭菌诱导效能,选择性和药理动力学特性.
主要方法:
- 新型DPP9抑制剂的合成和表征.
- 评估AML细胞和HIV-1感染的T淋巴细胞中激素灭亡诱导.
- 评估DPP9对DPP8,DPP4和其他酶的选择性.
- 在老鼠中对化合物6e的药理动力学研究.
主要成果:
- 新型DPP9抑制剂表现出前所未有的激素灭亡诱导功效和动力学.
- 化合物6e表现出相当大的DPP9-DPP8选择性和对DPP4的完全选择性.
- 化合物6e在老鼠中显示出高的口服生物可用性和长的体内和微体半衰期.
- 在HIV-1感染的T淋巴细胞中研究了激素灭亡诱导潜力.
结论:
- 这些新型DPP9抑制剂对AML和HIV-1具有显著的治疗潜力.
- 化合物6e是进一步药物开发的有希望的候选物,因为它具有有利的药理动力学特征.
- 开发的化合物作为探索DPP9在疾病中的作用的有价值的研究工具.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K

